【摘要】 目的 :观察拉米夫定 (3- TC)与干扰素 (IFN)联合与单用治疗慢性乙型病毒性肝炎 (CHB)的疗效。方法 :以 2种药物分别单用或联合应用 ,治疗 130例 CHB患者 ,观察治疗前后各自临床症状、AL T、病毒标志物水平的变化。结果 :治疗结束时联合用药组 HBV- DNA阴转率为 81.6 % (6 2 / 76 ) ,HBe Ag阴转率为 38.2 % (2 6 / 6 8) ,抗 - HBe阳转率为 2 5 % (17/ 6 8) ;单用 3TC组 HBV- DNA阴转率为 70 .8% (17/ 2 4) ,HBe Ag阴转率为 10 % (2 / 10 ) ,抗 - HBe阳转率为 5 % (1/ 2 0 ) ;单用 IFN组 HBV- DNA阴转率为 33.3% (10 / 30 ) ,HBe Ag阴转率为 40 % (12 / 30 ) ,抗 - HBe阳转率为 10 % (3/ 30 )。各组患者 AL T水平于 12周以后均正常。肝炎临床症状改善 ,应用 IFN者副作用稍多 ,但多数患者可以耐受治疗。结论 :联合用药组综合疗效优于单独用药组更多还原

【Abstract】 Objective:To evaluate the curative effect of using Lamivudine and Interferon for chronic hepatitis B.Methods:Lamivudine and Interferon separated or combined therapeutics application were took place in chronic hepatitis B patients and the dynamic variety about symptoms,ALT,viral marker before and after therapy were observed.Results:There was 81.6%(62/76)HBV DNA,38.2%(26/68)HBeAg negative rate and 25%(16/68) anti HBe positive rate in combined application group at the end of therapy.The Lamivudine or Interferon application alone showed 70.8%(17/24),33.3%(10/30)HBV DNA;10%(2/20),40%(12/30)HBeAg negative rate and 5%(1/20),10%(3/30)anti HBe positive rate respectively.All the sera ALT became normal after 12 weeks later.The symptoms of hepatitis were improved.The application of interferon showed more side effect,but commonly did not affect the therapeutics.Conclusion:There is a better curative effect in combined application group in general.更多还原